Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CoreValve Expands Percutaneous Aortic Valve Trial In Europe

This article was originally published in The Gray Sheet

  • News

Executive Summary

CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end

You may also be interested in...



Medtronic Expands Minimally Invasive Surgery Line With AF, Valve Products

Medtronic is developing a clinical trial for a minimally invasive ablation device for non-concomitant treatment of atrial fibrillation, or lone AF

Medtronic Expands Minimally Invasive Surgery Line With AF, Valve Products

Medtronic is developing a clinical trial for a minimally invasive ablation device for non-concomitant treatment of atrial fibrillation, or lone AF

Edwards Drives Less-Invasive Valves Via IDE Study, Eventual HDE

Edwards Lifesciences will pursue a humanitarian device exemption for its percutaneous heart valve only after trial enrollment is completed

Table

View full table

Tags:
Latest Headlines

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

See All
UsernamePublicRestriction

Register

MT021440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By